CK-102
/ Fortress, Teva
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 11, 2023
The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC).
(PubMed, BMC Pulm Med)
- "We identified an effective ferroptosis-related prognostic model based on single-cell sequencing. The potential prediction model is devoted to exploring clinical therapeutic targets for NSCLC."
Biomarker • Combination therapy • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
April 26, 2012
Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595)
(ASCO 2012)
- Presentation time: Mon, Jun 4, 8:00 AM - 12:00 PM; Anticipated presentation at ASCO 2012
Anticipated P1 data presentation • Oncology
May 16, 2012
Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595)
(ASCO 2012)
- Presentation time: Monday June 4, 8:00 AM to 12:00 PM; P1, N=26; The MTD of CEP-9722 in combination with TMZ (150 mg/m2) was reached at 1000 mg/day; Pharmacodynamic analysis demonstrated PARP inhibition at all doses
P1 data • Oncology
December 12, 2018
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
(PubMed, Curr Treat Options Oncol)
- "Olaparib, rucaparib, and niraparib all have indications for maintenance therapy in recurrent platinum-sensitive ovarian cancer after response to platinum-based therapy. Other newer agents such as talazoparib, veliparib, 2X-121, and CEP-9722 are in earlier stages of development. As more FDA-approved indications for PARP inhibitor therapy in ovarian cancer become available, we anticipate the decision of which PARP inhibitor to use will become increasingly complex."
Biomarker • BRCA Biomarker • Clinical • Journal • PARP Biomarker • Review
1 to 4
Of
4
Go to page
1